Przejdź do treściA recent meta-analysis of 13 randomized trials suggests that duloxetine may reduce opioid consumption after total hip and knee arthroplasty. At the same time, the average reduction in pain was small and, at most time points, did not reach the threshold considered clinically important.
Polish version: Duloksetyna po endoprotezoplastyce — mniej opioidów, mały efekt przeciwbólowy
Why is this study clinically relevant?
Duloxetine is a serotonin-noradrenaline reuptake inhibitor (SNRI) used, among other indications, for neuropathic pain and chronic pain syndromes. Interest in arthroplasty comes from its potential role in multimodal analgesia and opioid-sparing strategies. The clinically important question, however, is not only whether a difference is statistically significant, but whether it is large enough for patients to notice.
Study question and methodology
Ibrahim, Abdelnabi and Sheta analysed 13 randomized trials published between 2010 and 2024, including 1,176 patients after total hip or total knee arthroplasty. Outcomes included pain at rest and while walking, opioid consumption converted to morphine equivalents, and adverse events. Random-effects models were used when heterogeneity was substantial, with additional sensitivity analyses for selected outcomes.
Key results
- At 24 hours, duloxetine reduced pain at rest by an average of 5.09 mm and pain while walking by 4.55 mm on a 0–100 mm scale.
- At 2 weeks, the corresponding differences were 6.48 mm and 8.93 mm.
- Most of these differences were statistically significant, but remained below the 10 mm minimal clinically important difference adopted by the authors.
- Opioid use was lower by 22.74 mg morphine equivalents at 48 hours and by 10.58 mg at 72 hours. Heterogeneity for these analyses was extremely high, however: I² 100% and 97%, respectively.
- Nausea or vomiting occurred less often with duloxetine, while somnolence was more frequent.
Clinical interpretation for an orthopaedic surgeon
The most important finding is the gap between statistical significance and effect size. The results do not support the claim that duloxetine provides clearly superior pain control for the average patient after joint replacement. The opioid-sparing signal may nevertheless be clinically useful as one component of a broader multimodal analgesia protocol.
The reductions of 22.74 mg and 10.58 mg morphine equivalents should not be treated as precise, universally expected effects. With I² values of 97–100%, the individual studies differed so markedly that the pooled estimates are better interpreted as indicating a direction of effect than as predicting a specific benefit for a particular protocol.
Limitations
- Substantial heterogeneity affected many pain analyses and virtually all analyses of opioid consumption.
- Two open-label studies were judged to have a high risk of bias for subjective outcomes.
- One study did not use an intention-to-treat analysis.
- Several trials had problems with missing data or lacked a pre-registered analysis plan.
- When the more conservative Hartung–Knapp adjustment was applied, some apparently significant pain results were no longer statistically significant.
What might change in practice — and what does the study not prove?
The meta-analysis strengthens the argument that duloxetine may be considered as one element of an opioid-sparing strategy in appropriately selected patients. It does not justify routine use in every patient after THA or TKA, and it does not demonstrate a large, clinically important analgesic advantage. It also does not establish the optimal dose, timing, duration of treatment or the subgroup most likely to benefit.
Duloxetine has its own adverse-effect and interaction profile. Any perioperative use therefore needs to follow a defined protocol and individual assessment of contraindications rather than the meta-analysis result alone.
Reference
Ibrahim A, Abdelnabi M, Sheta RA. Duloxetine for postoperative pain management in total hip and knee arthroplasty: a systematic review and meta-analysis. Journal of Orthopaedic Surgery and Research. 2026;21:527. DOI: 10.1186/s13018-026-07176-6. Published 2 September 2026.
← Research Updates, Literature and Evidence-Based Medicine
Content prepared by: Tomasz Poboży - orthopaedic surgeon.